Viral Spike Protein Receptor Binding Blockade /Neutralization : Eli Lilly’s monoclonal antibody-LY-CoV555 and Regeneron -Roche 2 monoclonal antibody combination have FDA Emergency Use Authorization for use in early infection (prior to development of endogenous antibodies) in high risk patients.
ProTac molecular medicines contain VHL like sequence peptide tags chemically linked to a molecular agent with viral or host protein binding capabilities. ProTACs target the protein (viral nsp/structural proteins/ or complicit host proteins ) to E3 ubiquitin ligase which ultimately result in proteolysis by the Cytosolic Proteosome.